Cairo – Mubasher: Kahira Pharmaceuticals said Wednesday that its ordinary general meeting (OGM) has adopted the estimated budget draft and the investment plan for fiscal year 2017/2018, according to a bourse filing.
Earlier this month, the company said that it seeks to achieve an increase of 83.1% in its profits for FY17/18 to EGP 88.5 million, versus an estimated profit worth EGP 48.3 million for FY16/17.
Revenues are targeted at EGP 873.4 million in FY17/18, compared to estimated revenues of EGP 598 million in FY16/17.
The company set the investment budget at EGP 47.9 million, versus EGP 22.2 million for the current fiscal year.
